Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Potential of coconut oil and medium chain triglycerides in the prevention and treatment of Alzheimer’s disease

Chatterjee, P., Fernando, M., Fernando, B., Dias, C.B., Shah, T., Silva, R., Williams, S., Pedrini, S., Hillebrandt, H., Goozee, K., Barin, E., Sohrabi, H.R.ORCID: 0000-0001-8017-8682, Garg, M., Cunnane, S. and Martins, R.N. (2020) Potential of coconut oil and medium chain triglycerides in the prevention and treatment of Alzheimer’s disease. Mechanisms of Ageing and Development, 186 . Article 111209.

Link to Published Version: https://doi.org/10.1016/j.mad.2020.111209
*Subscription may be required

Abstract

Alzheimer’s disease (AD) is the most common form of dementia. Currently, there is no effective medication for the prevention or treatment of AD. This has led to the search for alternative therapeutic strategies. Coconut oil(CO) has a unique fatty acid composition that is rich in medium chain fatty acids(MCFA), a major portion of which directly reaches the liver via the portal vein, thereby bypassing the lymphatic system. Given that brain glucose hypometabolism is a major early hallmark of AD, detectable well before the onset of symptoms, ketone bodies from MCFA metabolism can potentially serve as an alternative energy source to compensate for lack of glucose utilisation in the brain. Additionally, neuroprotective antioxidant properties of CO have been attributed to its polyphenolic content. This review discusses how the metabolism of CO and MCFA may aid in compensating the glucose hypometabolism observed in the AD brain. Furthermore, we present the current evidence of the neuroprotective properties of CO on cognition, amyloid-β pathogenicity, inflammation and oxidative stress. The current review addresses the influence of CO/MCFA on other chronic disorders that are risk factors for AD, and addresses existing gaps in the literature regarding the use of CO/MCFA as a potential treatment for AD.

Item Type: Journal Article
Publisher: Elsevier
Copyright: © 2020 Published by Elsevier B.V.
URI: http://researchrepository.murdoch.edu.au/id/eprint/55550
Item Control Page Item Control Page